糖尿病肾病合并妊娠研究进展

doi:10.3760/cma.j.issn.1007-1245.2024.01.003

摘要/Abstract

摘要：

在世界范围内，妊娠期糖尿病孕妇的数量一直在稳步增加。这些妊娠会增加各种并发症的风险，包括流产、先天性畸形、巨大儿、胎儿生长受限、子痫前期、早产和死产。对于患有糖尿病肾病的孕妇来说，评估妊娠对肾功能的影响以及肾病对妊娠结局的影响是很重要的。肾功能和微量白蛋白尿正常的孕妇在怀孕期间肾功能丧失的风险较低，而肾小球滤过率<60 ml/min和/或蛋白尿≥3 g/24 h的孕妇在怀孕初期就有永久性肾脏损害的风险。胎儿和母亲并发症的风险与慢性肾脏疾病的严重程度和血糖控制相关。产前护理的进步改善了胎儿和产妇的结局。孕前咨询已成为所有糖尿病妇女，特别是糖尿病和慢性肾病妇女成功怀孕的关键。

关键词:

糖尿病肾病, 慢性肾脏病, 孕妇, 产前护理

Abstract:

The number of pregnant women with gestational diabetes has been steadily increasing worldwide. These pregnancies have elevated risk of various complications, including miscarriage, congenital abnormalities, macrosomia, fetal growth restriction, preeclampsia, preterm birth, and stillbirth. For pregnant women with diabetic nephropathy, it is crucial to assess the impact of pregnancy on kidney function and the influence of kidney disease on pregnancy outcomes. Pregnant women with normal kidney function and microalbuminuria have lower risk of kidney function loss during pregnancy, whereas those with a glomerular filtration rate < 60 ml/min and/or proteinuria ≥3 g/24 h in early pregnancy face risk of permanent kidney damage. The risk of complications for both the fetuses and mothers is associated with the severity of chronic kidney disease and glycemic control. Advancements in prenatal care have improved outcomes for both the fetuses and mothers. Preconception counseling has become a critical factor for the successful pregnancy of all diabetic women, especially those with diabetes and chronic kidney disease.

Key words:

Diabetic nephropathy, Chronic kidney disease, Pregnant women, Prenatal care

陈文清管保章.

糖尿病肾病合并妊娠研究进展 [J]. 国际医药卫生导报, 2024, 30(1): 15-20.

Chen Wenqing, Guan Baozhang.

Research progress on diabetic nephropathy complicated with pregnancy [J]. International Medicine and Health Guidance News, 2024, 30(1): 15-20.

参考文献

[1] Kitzmiller JL, Wallerstein R, Correa A, et al. Preconception care for women with diabetes and prevention of major congenital malformations [J]. Birth Defects Res A Clin Mol Teratol, 2010, 88(10): 791-803. DOI: 10.1002/bdra.20734.
[2] Persson M, Norman M, Hanson U. Obstetric and perinatal outcomes in type 1 diabetic pregnancies: a large, population-based study [J]. Diabetes Care, 2009, 32(11): 2005-2009. DOI: 10.2337/dc09-0656.
[3] Gordon M, Landon MB, Samuels P, et al. Perinatal outcome and long-term follow-up associated with modern management of diabetic nephropathy [J]. Obstet Gynecol, 1996, 87(3): 401-409. DOI: 10.1016/0029-7844(95)00420-3.
[4] Dunne FP, Chowdhury TA, Hartland A, et al. Pregnancy outcome in women with insulin-dependent diabetes mellitus complicated by nephropathy [J]. QJM, 1999, 92(8): 451-454. DOI: 10.1093/qjmed/92.8.451.
[5] Bramham K. Diabetic nephropathy and pregnancy [J]. Semin Nephrol, 2017, 37(4):362-369. DOI: 10.1016/j.semnephrol.2017.05.008.
[6] Podymow T, Joseph G. Preconception and pregnancy management of women with diabetic nephropathy on angiotensin converting enzyme inhibitors [J]. Clin Nephrol, 2015, 83(2): 73-79. DOI: 10.5414/CN108391.
[7] Carr DB, Koontz GL, Gardella C, et al. Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery [J]. Am J Hypertens, 2006, 19(5): 513-519. DOI: 10.1016/j.amjhyper.2005.12.010.
[8] Mathiesen ER, Ringholm L, Feldt-Rasmussen B, et al. Obstetric nephrology: pregnancy in women with diabetic nephropathy--the role of antihypertensive treatment [J]. Clin J Am Soc Nephrol, 2012, 7(12): 2081-2088. DOI: 10.2215/CJN.00920112.
[9] Ekbom P, Damm P, Feldt-Rasmussen B, et al. Pregnancy outcome in type 1 diabetic women with microalbuminuria [J]. Diabetes Care, 2001, 24(10): 1739-1744. DOI: 10.2337/diacare.24.10.1739.
[10] Kendrick JM. Preconception care of women with diabetes [J]. J Perinat Neonatal Nurs, 2004, 18(1): 14-25; quiz 26-27. DOI: 10.1097/00005237-200401000-00003.
[11] Young EC, Pires ML, Marques LP, et al. Effects of pregnancy on the onset and progression of diabetic nephropathy and of diabetic nephropathy on pregnancy outcomes [J]. Diabetes Metab Syndr, 2011, 5(3): 137-142. DOI: 10.1016/j.dsx.2012.02.013.
[12] Aldhaheri S, Baghlaf H, Badeghiesh A, et al. Should pregnant women with diabetes be counseled differently if nephropathy was detected? a population database study [J]. J Matern Fetal Neonatal Med, 2022, 35(25): 9614-9621. DOI: 10.1080/14767058.2022.2049749.
[13] Kornacki J, Boroń D, Gutaj P, et al. Diagnosis of preeclampsia in women with diabetic kidney disease [J]. Hypertens Pregnancy, 2021, 40(4): 322-329. DOI: 10.1080/10641955.2021.1987454.
[14] Bell R, Glinianaia SV, Tennant PW, et al. Peri-conception hyperglycaemia and nephropathy are associated with risk of congenital anomaly in women with pre-existing diabetes: a population-based cohort study [J]. Diabetologia, 2012. DOI: 10.1007/s00125-012-2455-y.
[15] Klemetti MM, Laivuori H, Tikkanen M, et al. Obstetric and perinatal outcome in type 1 diabetes patients with diabetic nephropathy during 1988-2011 [J]. Diabetologia, 2015, 58(4): 678-686. DOI: 10.1007/s00125-014-3488-1.
[16] Sibiak R, Gutaj P, Mrzewka-Rogacz B, et al. Novel continuous glucose monitoring metrics and large-for-gestational-age risk: an exploratory retrospective cohort study in pregnancies with type 1 diabetes [J]. Diabetes Technol Ther, 2022, 24(1): 42-53. DOI: 10.1089/dia.2021.0194.
[17] Søholm JC, Vestgaard M, Ásbjörnsdóttir B, et al. Potentially modifiable risk factors of preterm delivery in women with type 1 and type 2 diabetes [J]. Diabetologia, 2021, 64(9): 1939-1948. DOI: 10.1007/s00125-021- 05482-8.
[18] Kerssen A, Evers IM, de Valk HW, et al. Poor glucose control in women with type 1 diabetes mellitus and 'safe' hemoglobin A1c values in the first trimester of pregnancy [J]. J Matern Fetal Neonatal Med, 2003, 13(5): 309-313. DOI: 10.1080/jmf.13.5.309.313.
[19] Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors [J]. N Engl J Med, 2006, 354(23): 2443-2451. DOI: 10.1056/NEJMoa055202.
[20] Kennedy D, Koren G. Identifying women who might benefit from higher doses of folic acid in pregnancy [J]. Can Fam Physician, 2012, 58(4): 394-397.
[21] Chitayat D, Matsui D, Amitai Y, et al. Folic acid supplementation for pregnant women and those planning pregnancy: 2015 update [J]. J Clin Pharmacol, 2016, 56(2): 170-175. DOI: 10.1002/jcph.616.
[22] Wilson RD, Genetics Committee, Wilson RD, et al. Pre-conception folic acid and multivitamin supplementation for the primary and secondary prevention of neural tube defects and other folic acid-sensitive congenital anomalies [J]. J Obstet Gynaecol Can, 2015, 37(6): 534-552. DOI: 10.1016/s1701-2163(15)30230-9.
[23] Tsakiridis I, Mamopoulos A, Athanasiadis A, et al. Management of pregestational diabetes mellitus: a comparison of guidelines [J]. J Matern Fetal Neonatal Med, 2022, 35(3): 423-432. DOI: 10.1080/14767058. 2020.1719481.
[24] Spotti D. Pregnancy in women with diabetic nephropathy [J]. J Nephrol, 2019, 32(3):379-388. DOI: 10.1007/s40620-018-0553-8.
[25] Fu J, Tomlinson G, Feig DS. Increased risk of major congenital malformations in early pregnancy use of angiotensin-converting-enzyme inhibitors and angiotensin-receptor-blockers: a meta-analysis [J]. Diabetes Metab Res Rev, 2021, 37(8):e3453. DOI: 10.1002/dmrr.3453.
[26] Li DK, Yang C, Andrade S, et al. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study [J]. BMJ. 2011 Oct 18;343:d5931. doi: 10.1136/bmj.d5931. PMID: 22010128; PMCID:PMC3196564.
[27] Pearson DW, Kernaghan D, Lee R, et al. The relationship between pre-pregnancy care and early pregnancy loss, major congenital anomaly or perinatal death in type I diabetes mellitus [J]. BJOG, 2007,114(1): 104-107. DOI 10.1111/j.1471-0528.2006.01145.x.
[28] Jensen DM, Korsholm L, Ovesen P, et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes [J]. Diabetes Care, 2009, 32(6):1046-1048. DOI: 10.2337/dc08-2061.
[29] Galindo A, Burguillo AG, Azriel S, et al. Outcome of fetuses in women with pregestational diabetes mellitus [J]. J Perinat Med, 2006, 34(4): 323-331. DOI: 10.1515/JPM.2006.062.
[30] Greene MF, Hare JW, Cloherty JP, et al. First-trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy [J]. Teratology, 1989, 39(3): 225-231. DOI: 10.1002/tera. 1420390303.
[31] Evers IM, de Valk HW, Visser GH. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands [J]. BMJ, 2004, 328(7445): 915. DOI: 10.1136/bmj.38043.583160.EE.
[32] Cohen AL, Wenger JB, James-Todd T, et al. The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes [J]. Hypertens Pregnancy, 2014, 33(1): 81-92. DOI: 10.3109/10641955.2013.837175.
[33] Jensen DM, Damm P, Moelsted-Pedersen L, et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study [J]. Diabetes Care, 2004, 27(12): 2819-2823. DOI: 10.2337/diacare.27.12.2819.
[34] Casson IF. Pregnancy in women with diabetes--after the CEMACH report, what now? [J]. Diabet Med, 2006, 23(5): 481-484. DOI: 10.1111/j.1464-5491.2006.01896.x.
[35] Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care [J]. Diabetes Care, 2008, 31(5): 1060-1079. DOI: 10.2337/dc08-9020.
[36] Crowther CA, Alsweiler JM, Hughes R, et al. Tight or less tight glycaemic targets for women with gestational diabetes mellitus for reducing maternal and perinatal morbidity? (TARGET): study protocol for a stepped wedge randomised trial [J]. BMC Pregnancy Childbirth, 2018, 18(1):425. DOI: 10.1186/s12884-018-2060-2.
[37] Patti AM, Giglio RV, Pafili K, et al. Advances in pharmacological treatment of type 1 diabetes during pregnancy [J]. Expert Opin Pharmacother, 2019, 20(8): 983-989. DOI: 10.1080/14656566.2019.1593372.
[38] Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review [J]. JAMA, 2019, 321(18): 1811-1819. DOI: 10.1001/jama. 2019.4981.
[39] Ringholm L, Damm JA, Vestgaard M, et al. Diabetic nephropathy in women with preexisting diabetes: from pregnancy planning to breastfeeding [J]. Curr Diab Rep, 2016, 16(2): 12. DOI: 10.1007/s11892-015-0705-3.
[40] Gowda RM, Khan IA, Mehta NJ, et al. Cardiac arrhythmias in pregnancy: clinical and therapeutic considerations [J]. Int J Cardiol, 2003, 88(2-3): 129-133. DOI: 10.1016/s0167-5273(02)00601-0.
[41] Khandelwal M, Kumanova M, Gaughan JP, et al. Role of diltiazem in pregnant women with chronic renal disease [J]. J Matern Fetal Neonatal Med, 2002, 12(6): 408-412. DOI: 10.1080/jmf.12.6.408.412.
[42] Lewis H, Egerman R, Kazory A, et al. Diabetes and pregnancy: risks and opportunities [J]. Cleve Clin J Med, 2018, 85(8): 619-628. DOI: 10.3949/ccjm.85a.16138.
[43] American Diabetes Association. 13. Management of diabetes in pregnancy: standards of medical care in diabetes-2018 [J]. Diabetes Care, 2018, 41 Suppl 1: S137-S143. DOI: 10.2337/dc18-S013.
[44] James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [J]. JAMA, 2014, 311(5): 507-520. DOI: 10.1001/jama.2013.284427.
[45] Weber-Schoendorfer C, Hannemann D, Meister R, et al. The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study [J]. Reprod Toxicol, 2008, 26(1): 24-30. DOI: 10.1016/j.reprotox.2008.05.065.
[46] Magee LA, CHIPS Study Group, von Dadelszen P, et al. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial [J]. BJOG, 2016, 123(7): 1143-1151. DOI: 10.1111/1471-0528. 13569.
[47] Firoz T, Magee LA, MacDonell K, et al. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review [J]. BJOG, 2014, 121(10): 1210-1218, discussion 1220. DOI: 10.1111/1471-0528.12737.
[48] Rothberger S, Carr D, Brateng D, et al. Pharmacodynamics of clonidine therapy in pregnancy: a heterogeneous maternal response impacts fetal growth [J]. Am J Hypertens, 2010, 23(11): 1234-1240. DOI: 10.1038/ajh.2010.159.
[49] Askie LM, Duley L, Henderson-Smart DJ, et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data [J]. Lancet, 2007, 369(9575):1791-1798. DOI: 10.1016/S0140-6736(07)60712-0.
[50] Hu X, Liu W, Yan Y, et al. Vitamin D protects against diabetic nephropathy: Evidence-based effectiveness and mechanism [J]. Eur J Pharmacol, 2019, 845: 91-98. DOI: 10.1016/j.ejphar.2018.09.037.
[51] Plum LA, Zella JB. Vitamin D compounds and diabetic nephropathy [J]. Arch Biochem Biophys, 2012, 523(1): 87-94. DOI: 10.1016/j.abb.2012.02.008.
[52] Galuška D, Pácal L, Kaňková K. Pathophysiological implication of vitamin D in diabetic kidney disease [J]. Kidney Blood Press Res, 2021, 46(2): 152-161. DOI: 10.1159/000514286.